A Factor XIIa Inhibitory Antibody Provides Thromboprotection in Extracorporeal Circulation Without Increasing Bleeding Risk

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Science Translational Medicine

• Publication date

  2014-02-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1126/scitranslmed.3006804PMID 24500405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Continuous intravenous anaesthesia with sufentanil and midazolam in medetomidine premedicated New Zealand White rabbits

  2013cited by this paper
• A new phosphorylcholine-coated polymethylpentene oxygenator for extracorporeal membrane oxygenation: a preliminary experience

  2013cited by this paper
• Fibronectin coating of oxygenator membranes enhances endothelial cell attachment

  2013cited by this paper
• [New anticoagulants].

  2013cited by this paper
• Bleeding and antidotes in new oral anticoagulants.

  2013cited by this paper
• Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates

  2013cited by this paper
• Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy.

  2013cited by this paper
• Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin.

  2011cited by this paper
• Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.

  2011cited by this paper
• Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo.

  2011cited by this paper
• Activation of the Hemostatic System During Cardiopulmonary Bypass

  2011cited by this paper
• Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice.

  2010cited by this paper
• Update on Antithrombotic Therapy: New Anticoagulants

  2010cited by this paper
• Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis.

  2010cited by this paper
• Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin.

  2010cited by this paper
• Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis

  2010cited by this paper
• Factor XIIa Inhibitor Recombinant Human Albumin Infestin-4 Abolishes Occlusive Arterial Thrombus Formation Without Affecting Bleeding

  2010influential reference
• A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo.

  2010cited by this paper
• In vivo roles of factor XII.

  2010cited by this paper
• Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation

  2009cited by this paper
• Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis

  2009cited by this paper
• Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.

  2009cited by this paper
• Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis.

  2009cited by this paper
• Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI.

  2009cited by this paper
• Reduced incidence of ischemic stroke in patients with severe factor XI deficiency.

  2008cited by this paper
• Triggers, targets and treatments for thrombosis

  2008cited by this paper
• Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation

  2007cited by this paper
• Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery

  2006cited by this paper
• Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis

  2006cited by this paper
• Extracorporeal Life Support Registry Report 2004

  2005cited by this paper
• Defective thrombus formation in mice lacking coagulation factor XII

  2005cited by this paper
• The impact of heparin-coated circuits on hemodynamics during and after cardiopulmonary bypass.

  2005cited by this paper
• International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences

  2005cited by this paper
• Role of tissue factor in hemostasis, thrombosis, and vascular development.

  2004cited by this paper
• Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo

  2004cited by this paper
• Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion.

  2004cited by this paper
• Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries.

  2004cited by this paper
• The Occasional Venous Thromboses Seen in Patients with Severe (Homozygous) FXII Deficiency are Probably Due to Associated Risk Factors: A Study of Prevalence in 21 Patients and Review of the Literature

  2004cited by this paper
• Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates.

  2003cited by this paper
• The effects of nitric oxide on coagulation during simulated extracorporeal membrane oxygenation.

  2000cited by this paper
• A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C1 esterase inhibitor.

  2000cited by this paper
• A Monoclonal Antibody Raised against Human β-factor XIIa which also Recognizes α-factor XIIa but not Factor XII or Complexes of Factor XIIa with C1 Esterase Inhibitor

  2000cited by this paper
• Reduced platelet activation and thrombosis in extracorporeal circuits coated with nitric oxide release polymers

  2000cited by this paper
• High Molecular Weight Kininogen Utilizes Heparan Sulfate Proteoglycans for Accumulation on Endothelial Cells*

  2000cited by this paper
• Recombinant Kunitz Protease Inhibitory Domain of the Amyloid β-Protein Precursor as an Anticoagulant in Venovenous Extracorporeal Circulation in Rabbits

  1999cited by this paper
• Mapping of the Discontinuous H-kininogen Binding Site of Plasma Prekallikrein

  1999cited by this paper
• Haemocompatibility of paediatric membrane oxygenators with heparin-coated surfaces

  1999cited by this paper
• Reevaluation of the Incidence of Thromboembolic Complications in Congenital Factor XII Deficiency

  1999cited by this paper
• Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin.

  1998cited by this paper
• Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation.

  1996cited by this paper
• Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation.

  1995cited by this paper
• John Hageman's factor and deep‐vein thrombosis: Leiden Thrombophilia Study

  1994cited by this paper
• α1-Antitrypsin Pittsburgh (Met358 → Arg) Inhibits the Contact Pathway of Intrinsic Coagulation and Alters the Release of Human Neutrophil Elastase during Simulated Extracorporeal Circulation

  1994cited by this paper
• The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons.

  1993cited by this paper
• Aprotinin in cardiopulmonary bypass--effects on the Hageman factor (FXII)--Kallikrein system and blood loss.

  1992cited by this paper
• Monitoring of factor XII activity and granulocyte elastase release during cardiopulmonary bypass.

  1991cited by this paper
• Designer and catalytic antibodies.

  1990cited by this paper
• A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation.

  1987cited by this paper
• Production and characterization of a murine monoclonal antibody against a heavy chain of Hageman factor (factor XII).

  1985cited by this paper
• A monoclonal antibody that inhibits activation of human Hageman factor (factor XII).

  1985cited by this paper
• Thrombosis or Myocardial Infarction in Congenital Clotting Factor Abnormalities and Chronic Thrombocytopenias: A Report of 21 Patients and a Review of 50 Previously Reported Cases

  1983cited by this paper
• Prostacyclin in lieu of anticoagulation with heparin for extracorporeal circulation.

  1981cited by this paper
• Activation of the classical pathway of complement by Hageman factor fragment

  1981cited by this paper
• Hageman factor deficiency and oral contraceptives.

  1980cited by this paper
• Stereological Methods. Practical methods for biological morphometry

  1979cited by this paper
• The Demise of John Hageman

  1968cited by this paper

• Novel and Experimental Anticoagulant Strategies Beyond Current DOACs.

  2026cites this paper
• Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present).

  2026cites this paper
• Endothelial barrier disruption and contact system modulation during bacterial infection.

  2026cites this paper
• Thiol isomerase ERp46 catalyzes the disulfide formation of coagulation factor XII enhancing its activity.

  2025cites this paper
• ECMO-induced coagulopathy: strategic initiatives for research and clinical practice (a workshop report of the NHLBI)

  2025cites this paper
• Citrate regional anticoagulation of 500 ml/min of extracorporeal blood flow: an experimental study

  2025cites this paper
• Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis

  2025cites this paper
• Anticoagulation during Extracorporeal Membrane Oxygenation (ECMO): A Selective Inhibitor of Activated Factor XII Compared to Heparin in an Ex Vivo Model.

  2025cites this paper
• Targeting the Contact-Kinin System: A Cyclopeptide with Anti-Thromboinflammatory Properties Against Stroke.

  2025cites this paper
• Inhibition of FXIIa attenuates kidney fibrosis in mice with unilateral ureteral obstruction

  2025cites this paper
• The factor XIa antibody osocimab strongly inhibits clotting in extracorporeal circuits with human blood and in baboons

  2025cites this paper
• Factor XII–driven coagulation traps bacterial infections

  2025cites this paper
• Nanomedicine for venous thrombosis: Insights from an inflammatory perspective.

  2025cites this paper
• A novel polypeptide from stony coral Goniopora columna inhibits thrombosis by interfering with the contact-kinin pathway

  2025cites this paper
• Catheter‐related deep vein thrombosis: Where are we at and where are we going? Updates and ongoing unmet clinical needs

  2024cites this paper
• ECMO aggravates platelet GPV shedding and δ-granule deficiency in COVID-19-associated acute respiratory distress syndrome.

  2024cites this paper
• The Future of Therapeutic Options for Hereditary Angioedema.

  2024cites this paper
• New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants

  2024cites this paper
• Hemostatic derangements associated with cardiopulmonary bypass predict outcomes in pediatric patients undergoing corrective heart surgery.

  2024cites this paper
• Antithrombotic Therapy Following Structural Heart Disease Interventions: Current Status and Future Directions

  2024cites this paper
• FXII contact activation is dependent on binding through two unique patches in its EGF-1 domain and can be prevented by (VHH) targeting.

  2024cites this paper
• Targeting factor XIIa for therapeutic interference with hereditary angioedema

  2024influential citation
• Risk Factors for Internal Jugular Vein Thrombosis 1 Month After Non-Cuffed Hemodialysis Catheter Removal

  2024cites this paper
• Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease.

  2024cites this paper
• The current landscape of Factor XI inhibitors

  2024cites this paper
• Biomimetic Anticoagulated Porous Particles with Self‐Reporting Structural Colors

  2024cites this paper
• Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors

  2024cites this paper
• An Update on Polyphosphate In Vivo Activities

  2024cites this paper
• Steps Toward Recapitulating Endothelium: A Perspective on the Next Generation of Hemocompatible Coatings.

  2024cites this paper
• Structural basis for the inhibition of βFXIIa by garadacimab.

  2024cites this paper
• Heparin Resistance in Patients Receiving Extracorporeal Membrane Oxygenation: A Review

  2024cites this paper
• The third-generation anticoagulants: factors XI, XII, and XIII inhibitors

  2024cites this paper
• Mimicking Mytilus edulis foot protein: A versatile strategy for robust biomedical coatings

  2024cites this paper
• Progress towards permanent respiratory support

  2024cites this paper
• Clotting of the Extracorporeal Circuit in Hemodialysis: Beyond Contact-Activated Coagulation.

  2024cites this paper
• A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation

  2024cites this paper
• Neutrophils: a key component in ECMO-related acute organ injury

  2024cites this paper
• HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure

  2023cites this paper
• Outcomes of heparinized adult veno-arterial extracorporeal membrane oxygenation patients managed with low and high activated partial thromboplastin time targets: A systematic review and meta-analysis

  2023cites this paper
• Prevalence of FXII-Deficiency and Its Relevance to Monitoring Anticoagulation in Adults Receiving Extracorporeal Membrane Oxygenation

  2023cites this paper
• Advances in Enhancing Hemocompatibility of Hemodialysis Hollow-Fiber Membranes

  2023cites this paper
• NETs-Induced Thrombosis Impacts on Cardiovascular and Chronic Kidney Disease

  2023cites this paper
• An evolutionary history of F12 gene: Emergence, loss, and vulnerability with the environment as a driver

  2023cites this paper
• Tissue Injury Protection: The Other Face of Anticoagulant Treatments in the Context of Ischemia and Reperfusion Injury with a Focus on Transplantation

  2023cites this paper
• Incidence of factor XII deficiency in critically ill patients with a prolonged activated partial thromboplastin time: a prospective observational study

  2023cites this paper
• Targeting the Contact Pathway of Coagulation for the Prevention and Management of Medical Device-Associated Thrombosis

  2023cites this paper
• Anticoagulants in adult extracorporeal membrane oxygenation: alternatives to standardized anticoagulation with unfractionated heparin

  2023cites this paper
• Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XI

  2023cites this paper
• The History of Extracorporeal Membrane Oxygenation and the Development of Extracorporeal Membrane Oxygenation Anticoagulation

  2023cites this paper
• MarioHeart: Novel In-Vitro Flow Model for Testing Heart Valve Prostheses and Anticoagulant Therapies

  2023cites this paper
• Shear‐Responsive Drug Delivery Systems in Medical Devices: Focus on Thrombosis and Bleeding

  2023cites this paper
• DOACs in the Anticoagulation of Mechanical Valves: A Systematic Review and Future Perspectives

  2023cites this paper
• Current and future strategies to monitor and manage coagulation in ECMO patients

  2023cites this paper
• Factors XI and XII in extracorporeal membrane oxygenation: longitudinal profile in children

  2023cites this paper
• Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease.

  2023cites this paper
• Anticoagulation in the ICU: a future for contact pathway inhibition?

  2023cites this paper
• Factor XII promotes the thromboinflammatory response in a rat model of veno-arterial extracorporeal membrane oxygenation.

  2023cites this paper
• Anticoagulation Strategies during Extracorporeal Membrane Oxygenation: A Narrative Review

  2022cites this paper
• The Journey Through the Pathogenesis and Treatment of Venous Thromboembolism in Inflammatory Bowel Diseases: A Narrative Review

  2022cites this paper
• Amide-functionalized 1,2,4-Triazol-5-amines as Covalent Inhibitors of Blood Coagulation Factor XIIa and Thrombin.

  2022cites this paper
• Fit-for-purpose validation of a drug-tolerant immunogenicity assay for a human mAb drug in animal safety studies.

  2022cites this paper
• Intrinsic coagulation pathway-mediated thrombin generation in mouse whole blood

  2022cites this paper
• Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment

  2022cites this paper
• Engineering the Cyclization Loop of MCoTI-II Generates Targeted Cyclotides that Potently Inhibit Factor XIIa.

  2022cites this paper
• Glycated albumin modulates the contact system with implications for the kallikrein-kinin and intrinsic coagulation systems

  2022cites this paper
• Bifunctional fusion protein targeting both FXIIa and FXIa displays potent anticoagulation effects.

  2022cites this paper
• Mechanisms for Reduced Fibrin Clot Formation on Liquid‐Infused Surfaces

  2022cites this paper
• Factor XII Explored with AlphaFold - Opportunities for Selective Drug Development

  2022cites this paper
• Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders

  2022cites this paper
• Veno-Arterial Extracorporeal Membrane Oxygenation (ECMO) Impairs Bradykinin-Induced Relaxation in Neonatal Porcine Coronary Arteries

  2022cites this paper
• Supercomputer Search for the New Inhibitors of the Coagulation Factor XIIa

  2022cites this paper
• Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation

  2022cites this paper
• A fibrin enhanced thrombosis model for medical devices operating at low shear regimes or large surface areas

  2022cites this paper
• Interactive Hemocompatible Nanocoating to Prevent Surface‐Induced Coagulation in Medical Devices

  2022cites this paper
• DDDT_A_353088 1667..1678

  2022cites this paper
• The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology

  2022cites this paper
• The Antithrombotic Effect of Recombinant Neorudin on Thrombi

  2022cites this paper
• Triazol-1-yl Benzamides Promote Anticoagulant Activity via Inhibition of Factor XIIa.

  2022cites this paper
• An Update on Safe Anticoagulation.

  2022cites this paper
• Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?

  2022cites this paper
• Insights in the Prothrombotic Changes After Implantation of a Left Ventricular Assist Device in Patients With End-Stage Heart Failure: A Longitudinal Observational Study

  2022cites this paper
• Novel contact–kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke

  2022cites this paper
• Titanium is a potent inducer of contact activation: implications for intravascular devices.

  2022cites this paper
• Factor XII Silencing Using siRNA Prevents Thrombus Formation in a Rat Model of Extracorporeal Life Support

  2022cites this paper
• New Blood Coagulation Factor XIIa Inhibitors: Molecular Modeling, Synthesis, and Experimental Confirmation

  2022cites this paper
• Extracorporeal Membrane Oxygenation in Critically Ill Children.

  2022cites this paper
• Coagulation factors XI and XII as possible targets for anticoagulant therapy.

  2022cites this paper
• Experimentally Validated Novel Factor XIIa Inhibitors Identified by Docking and Quantum Chemical Post‐processing

  2022cites this paper
• Early predictors of oxygenator exchange during veno-venous extracorporeal membrane oxygenation: A retrospective analysis

  2022cites this paper
• Factor XII plays a pathogenic role in organ failure and death in baboons challenged with Staphylococcus aureus

  2021cites this paper
• Hemocompatibility enhancement of polyethersulfone membranes: Strategies and challenges

  2021cites this paper
• Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents

  2021cites this paper
• Thrombosis and Haemostasis Pharmacological inhibition of Factor XIIa attenuates abdominal aortic an- eurysm, reduces atherosclerosis, and stabilizes atherosclerotic plaques

  2021cites this paper
• A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab

  2021cites this paper
• Factor XIII Activity Might Already Be Impaired before Veno-Venous ECMO in ARDS Patients: A Prospective, Observational Single-Center Cohort Study

  2021cites this paper
• Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312)

  2021cites this paper
• Sulfated poly-amido-saccharides (sulPASs) are anticoagulants in vitro and in vivo

  2021cites this paper
• Thromboembolic Prophylaxis in Traumatic Brain Injury

  2021cites this paper
• An update on factor XII-driven vascular inflammation.

  2021cites this paper
• Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation

  2021cites this paper